Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion

Hakyoung Kim, Dongryul Oh, Yong Chan Ahn, Keunchil Park, Myung-Ju Ahn, Se-Hoon Lee, Jong-Mu Sun, Young Mog Shim, Jae III Zo, Yong Soo Choi, Hong Kwan Kim and Jong Ho Cho

Abstract

Background: Oesophageal cancer with airway invasion presents a challenge for therapy and often has serious complications. We analysed the clinical outcomes of radiation therapy (RT) in patients with clinical T4b oesophageal cancer with airway invasion.

Methods: We retrospectively reviewed the medical records of 73 patients with oesophageal cancer who had clinical T4 disease and who received RT between January 1994 and June 2017. Among them, 47 patients with clinical T4b disease with airway invasion were included in this study; 31 had gross invasion on bronchoscopy and 16 had extrinsic compression with mucosal change. We investigated the survival outcomes, clinical courses, and toxicities.

Results: The median survival (MS) time was 9 months. The 1- and 2-year overall survival (OS) rates were 41.4 and 27.4%, respectively. The MS times for patients treated with curative or palliative aims were 15 and 4 months, respectively ($p = 0.001$). Seven patients (14.9%) had fistulae at diagnosis; after RT, three had no change in size, three closed, and one had increased. Newly developed oesophageal fistulae after treatment were observed in 13 patients (27.7%). The median time to a newly developed fistula was 3 months (range, 1–15). Among them, a fistula was closed in only one patient. Death from aspiration pneumonia occurred in one patient who had a fistula at diagnosis and in nine patients who newly developed fistulae after treatment. Severe oesophageal bleeding causing death occurred in two patients. Patients with gross invasion on bronchoscopy had a higher risk of developing a fistula than did patients with mucosal change (37.5% vs. 25.0%, respectively).

Conclusions: Even for clinical T4b disease with airway invasion, RT with a curative aim showed acceptable survival outcomes in patients with good performance status and no distant metastasis at initial diagnosis. However, the risk of fistula development associated with fatal events remains high. Further study is warranted to decrease the risks of treatment and improve clinical outcomes.

Trial registration: Retrospectively registered.

Keywords: T4b oesophageal cancer, Radiation therapy, Oesophageal fistula
Background
In patients with oesophageal cancer, airway invasion with or without a fistula was considered a contraindication for radiation therapy (RT) and associated with a dismal prognosis. Left untreated, patients developed pulmonary infections and sepsis with median survivals of only 1 to 6 weeks [1, 2]. However, RT significantly improved the survival rate compared to that for only supportive care [2, 3]. Additionally, closures of fistulae and occasional long-term survivors were reported. Several studies reported a significant improvement in local control and overall survival with concurrent chemoradiotherapy (CCRT) compared with RT alone, even though it was associated with severe complications [4–9]. In the current National Comprehensive Cancer Network (NCCN) guidelines, definitive CCRT is recommended for the treatment of patients with clinical T4b oesophageal cancer, and chemotheraphy alone can be considered in cases of tracheal invasion. RT can alleviate symptoms and increase the chance of cure for oesophageal cancer patients with airway invasion with or without a fistula, but the treatment can have severe complications. In this study, we reviewed the clinical course of cT4b oesophageal cancer patients with airway invasion, who received RT.

Methods
Patients
After receiving approval from the Institutional Review Board (IRB), we retrospectively reviewed the medical records of 73 patients with oesophageal cancer who had clinical T4 disease and who received RT between January 1994 and June 2017. Among them, 47 patients with clinical T4b disease and airway invasion were included. Patients with (1) clinical T4a disease invading the pleura, pericardium, or diaphragm (N = 16), (2) clinical T4b disease without bronchoscopy (N = 7), (3) clinical T4b disease with other structural involvement (N = 2), and (4) follow-up loss less than 1 month after the end of RT (N = 1) were excluded.

Diagnostic and staging scheme
All tumours were staged based on the seventh edition of the American Joint Committee on Cancer (AJCC) criteria. The tumour assessment consisted of complete history-taking, physical examination, complete blood counts, chemistry profiles, chest radiography, esophageogastroduodenoscopy (EGD) with biopsy, and a computed tomography (CT) scan of the chest and upper abdomen. Bronchoscopy with or without biopsy was performed when tumour invasion into the wall of the trachea and/or bronchus was suspected. Whole-body 18F-fluorodeoxyglucose positron-emission tomography with CT (FDG-PET-CT) scans were performed for diagnosis and staging.

Treatment
All patients underwent contrast-enhanced CT for RT simulation. Primary tumours and metastatic lymph nodes were delineated as the gross tumour volume (GTV) based on imaging and endoscopic findings. The clinical target volume (CTV) of the primary tumour included the primary GTV plus 2- to 3-cm margins in the craniocaudal directions and a 0.5-cm margin in the circumference. The nodal CTV was delineated by placing a 1-cm margin in all directions from the nodal GTV. The planning target volume (PTV) was defined as a 0.5- to 0.7-cm margin in all directions from the CTV to account for respiratory motion and daily setup errors. The planned total dose depended on the therapeutic aim, as described in Table 1. Nearly all patients received three-dimensional conformal RT (3D-CRT), typically through three or four coplanar fields using 4-, 6-, or 10-MV photons from a linear accelerator. Intensity-modulated radiation therapy (IMRT) was widely used toward the end of 2016 to treat oesophageal cancer in our institution and was administered to nine patients (19.1%) in this study who were treated with a curative aim. Two cycles of intravenous chemotherapy (5-fluorouracil [5-FU] 1000 mg/m2/day for 4 consecutive days plus cisplatin 60 mg/m2/day on the first day) were administered at 3-week intervals for definitive CCRT.

Surveillance
The patients were evaluated at 1 month after RT, then were asked to visit every 3 to 4 months for 2 years and every 6 months thereafter to detect disease progression during follow-up. EGD or imaging study with either chest CT or PET-CT scans was performed on each visit. The Revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (Version 1.1) were used for tumour response evaluation. The toxicities were evaluated according to the criteria of the Common Terminology Criteria for Adverse Events (CTCAE v.4.03).

Statistical analysis
Overall survival (OS) was defined as the time from the start date of the initial treatment until the date of death from any cause or until the latest documented follow-up. The survival rates were estimated using the Kaplan–Meier method and were compared using log-rank tests for categorical variables. To compare the incidence of fistula development according to the bronchoscopic findings, chi-squared or Fisher's exact tests were used. \( P < 0.05 \) was considered statistically significant in two-tailed tests.
Statistical analysis was performed using IBM SPSS Statistics for Window, version 24.0 (IBM Corp., Armonk, NY, USA).

Results

Patient and tumour characteristics

The overall patient and tumour characteristics are described in Table 1. The median age of the population was 62 years (range, 44 to 84 years). A large proportion of the population was male (95.7%). Most of the tumours were located in the upper or middle thorax (38.3 and 51.1%, respectively) and all showed squamous-cell carcinoma in the pathologic report. Among the 47 patients with clinical T4b disease and airway invasion on chest CT, gross invasion was confirmed by bronchoscopy in 31 (66.0%, Fig. 1a) and mucosal change was observed in 16 (34.0%, Fig. 1b). Most of the patients were treated with a curative aim (78.7%), except for 10 patients treated with a palliative aim because of either distant metastasis at initial diagnosis (six patients) or poor performance status (four patients). Among the patients treated with neoadjuvant CCRT, all underwent operation except for one patient who had a cardiac event during RT and stopped therapy at 20 Gy/10Fx.

Survival outcomes

The median follow-up duration was 8 months (range, 1 to 93 months). The median survival (MS) time was 9 months. The 1- and 2-year OS rates were 41.4 and 27.4%, respectively. The MS times for patients treated with curative or palliative aims were 15 and 4 months, respectively ($p = 0.001$) (Fig. 2). For cases with a curative aim, the 1- and 2-year OS rates were 51.8 and 34.3%, respectively, for 10 patients treated with a palliative aim because of either distant metastasis at initial diagnosis (six patients) or poor performance status (four patients). Among the patients treated with neoadjuvant CCRT, all underwent operation except for one patient who had a cardiac event during RT and stopped therapy at 20 Gy/10Fx.

Clinical courses and toxicities

Among the 47 patients with clinical T4b disease and airway invasion, seven (14.9%) had a fistula at diagnosis. Although fistula formation was observed, none of the patients had a fever or associated pneumonia. All patients reported severe dysphagia caused by the primary tumour. The clinical courses of patients with a malignant oesophageal fistula at initial diagnosis are

Table 1 Patient and tumor characteristics ($n = 47$)

| Characteristics                        | Number of patients | %     |
|----------------------------------------|--------------------|-------|
| Age [years; median (range)]            | 62 (44–84)         |       |
| Gender                                 |                    |       |
| Male                                   | 45                 | 95.7  |
| Female                                 | 2                  | 4.3   |
| ECOG performance status                |                    |       |
| 1                                      | 33                 | 70.2  |
| 2                                      | 13                 | 27.7  |
| 3                                      | 1                  | 2.1   |
| Tumor site                             |                    |       |
| Cervical                               | 5                  | 10.6  |
| Upper thoracic                         | 18                 | 38.3  |
| Middle thoracic                        | 24                 | 51.1  |
| Clinical T4b categorya                 |                    |       |
| Gross invasion in bronchoscopy         | 31                 | 66.0  |
| Mucosal change in bronchoscopy         | 16                 | 34.0  |
| Stage (AJCC 7th)                       |                    |       |
| IIIC                                   | 41                 | 87.2  |
| IV                                     | 6                  | 12.8  |
| Treatment                              |                    |       |
| Definitive CCRT                        | 20                 | 42.5  |
| Definitive RT alone                    | 7                  | 15.0  |
| Induction CT followed by RT            | 4                  | 8.5   |
| Neoadjuvant CCRT                       | 8                  | 17.0  |
| Palliative RT                          | 8                  | 17.0  |
| Radiotherapy dose                      |                    |       |
| −39 Gy                                 | 10                 | 21.3  |
| 40–49 Gy                               | 9                  | 19.1  |
| 50–59 Gy                               | 5                  | 10.6  |
| 60–70 Gy                               | 23                 | 49.0  |
| Radiotherapy technique                 |                    |       |
| 3DCRT                                  | 38                 | 80.9  |
| IMRT                                   | 9                  | 19.1  |

Abbreviation: ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer, CCRT Concurrent chemoradiotherapy, RT radiotherapy, CT chemotherapy, 3DCRT 3-dimensional conformal radiation therapy, IMRT Intensity-modulated radiotherapy

*aSuspicious airway invasion on computed tomography image*
summarized in Table 2. Definitive RT or CCRT with a planned total dose of 60 Gy or greater was delivered to five patients, except for two patients who received palliative RT because of poor performance status. After RT, three patients had no change in fistula size, three fistulae had closed, and one fistula was aggravated. Two of the three patients who showed a closing of their fistula could eat a normal regular diet at the last follow-up date. One patient who remained on tube feeding and showed closing of the fistula at the last visit died from an unknown cause.

Newly developed oesophageal fistulae after treatment were observed in 13 patients (27.7%, Fig. 4). The median time from treatment initiation to fistula diagnosis was 3 months (range, 1–15). The clinical courses of patients with oesophageal fistulae newly developed after treatment are summarized in Table 3. The fistula closed in one of the 13 patients during

**Fig. 1** Chest CT and bronchoscopy images in patients with gross invasion (a) and mucosal change (b) on bronchoscopy.
the follow-up; he could eat a normal regular diet at the last follow-up date. Nine patients died from aspiration pneumonia. Despite the lack of statistical significance due to the limited number of cases \((p = 0.770)\), disease with gross invasion on bronchoscopy showed a higher incidence of fistula development than did disease with mucosal change \((37.5\% \text{ vs. } 25.0\%\), respectively). In addition, a higher dose was not associated with a higher risk of fistula formation \((p = 0.141)\). Patients treated with < 60 Gy \((9/21 \text{ patients, } 42.9\%)\) showed a higher risk of developing fistula compared to that in patients treated with \(\geq 60 \text{ Gy} \ (4/19, 21.1\%)\).

Severe oesophageal bleeding causing death occurred in two patients, including one who developed a fistula at once and died immediately after diagnosis. There was no interruption in RT except for two patients who had jejunostomy wound infection and cardiac event during RT, respectively.

**Table 2** Clinical courses of patients with malignant esophageal fistula at initial diagnosis

| No. | Age/Sex | PS | Site | Treatment | RT technique | Change of fistula | Diet at last f/u | Survival (month) | Status |
|-----|---------|----|------|-----------|--------------|-----------------|-----------------|------------------|--------|
| 1   | 53/M    | 2  | BEF  | Palliative RT, 30Gy/10Fx | 3DCRT         | Closed at 2 months after RT | Tube feeding    | 2                | Dead of unknown cause |
| 2   | 56/F    | 1  | TEF  | Definitive CCRT with FP, 66Gy/33Fx | 3DCRT         | Closed\(^a\) | Oral intake | 93               | Alive with no evidence of disease\(^a\) |
| 3   | 68/M    | 1  | TEF  | Definitive RT alone, 60Gy/20Fx | 3DCRT         | Closed at 2 months after RT | Oral intake    | 6                | Dead of disease |
| 4   | 62/M    | 1  | TEF  | Definitive CCRT with FP, 70Gy/35Fx | 3DCRT         | No change | Tube feeding | 8                | Dead of unknown cause |
| 5   | 58/M    | 2  | TEF  | Palliative RT, 45Gy/18Fx | 3DCRT         | Aggravated | Tube feeding | 10               | Dead of disease (aspiration pneumonia) |
| 6   | 60/M    | 1  | BEF  | Definitive RT alone, 22Gy /11Fx (incomplete) | 3DCRT         | No change | Tube feeding | 3                | Dead of disease |
| 7   | 54/M    | 1  | T-BEF| Definitive CCRT with FP, 60Gy/30Fx | IMRT         | No change | Tube feeding | 12               | Alive with disease |

**Abbreviation:** PS performance status, RT radiotherapy, BEF bronchoesophageal fistula, TEF tracheoesophageal fistula, T-BEF tracheobronchial esophageal fistula, CCRT Concurrent chemoradiotherapy, 3DCRT 3-dimensional conformal radiation therapy, IMRT Intensity-modulated radiotherapy

\(^a\)Closing of fistula was found at 6 months’ follow-up. She performed Ivor-Lewis operation due to persistent residual mass and pathology showed complete response
Discussion
In patients with oesophageal cancer, airway invasion with or without a fistula presents a challenge for therapy. In previous studies, the use of CCRT demonstrated long-term survival and closing of fistulae in a minority of patients. The first study from Japan [10] showed promising results of CCRT for patients with an oesophageal fistula. Closing of the fistula was observed in 71% of patients, with an MS time of 6.6 months from the fistula diagnosis. Later, the use of 60 Gy CCRT in 30 fractions with a protracted infusion of 5-FU and cisplatin for clinical T4 oesophageal cancer including both T4a

Table 3 Clinical courses of patients with esophageal fistula newly developed after treatment

| No. | Age/Sex | PS | Treatment                        | Time to fistula formation | Site Management | Diet at last f/u | Survival (month) | Status              |
|-----|---------|----|----------------------------------|---------------------------|-----------------|------------------|------------------|-------------------|-------------------|
| 1   | 60/M    | 1  | Definitive CCRT, 62Gy/34Fx       | 6 months                  | TEF, Feeding- jejunostomy | Tube feeding    | 8                | DOD (aspiration pneumonia) |
| 2   | 65/M    | 1  | Definitive RT alone, 54Gy/18Fx   | 1 month                   | TEF, PEG        | Tube feeding    | 2                | DOD (aspiration pneumonia) |
| 3   | 68/M    | 1  | Neoadjuvant CCRT, 45Gy/25Fx      | 15 months                 | TEF, None       | None            | 15               | DOD (aspiration pneumonia, bleeding) |
| 4   | 68/M    | 2  | Palliative RT, 30Gy/10Fx         | 1 month                   | BEF, PEG        | Tube feeding    | 3                | DOD (aspiration pneumonia) |
| 5   | 54/M    | 1  | Palliative RT, 30Gy/12Fx         | 3 months                  | BEF, PEG        | Tube feeding    | 4                | DOD (aspiration pneumonia) |
| 6   | 74/M    | 2  | Definitive RT alone, 60Gy/20Fx   | 3 months                  | TMF, PRG        | Tube feeding    | 4                | DOD (disease progression) |
| 7   | 65/M    | 2  | Palliative RT, 30Gy/10Fx         | 3 months                  | TEF, Feeding- jejunostomy | Tube feeding    | 7                | DOD (aspiration pneumonia) |
| 8   | 63/M    | 1  | Neoadjuvant CCRT, 44Gy/22Fx      | 1 month                   | BEF, Feeding- jejunostomy | Oral intake    | 29               | Alive with no evidence of diseasea |
| 9   | 61/M    | 3  | Palliative RT, 30Gy/10Fx         | 1 month                   | TEF, PEG        | Tube feeding    | 4                | DOD (aspiration pneumonia) |
| 10  | 48/M    | 1  | Palliative RT, 39Gy/13Fx         | After ICT                 | TEF, PEG        | Tube feeding    | 6                | DOD (aspiration pneumonia) |
| 11  | 70/M    | 2  | Palliative RT, 39Gy/13Fx         | After ICT                 | BEF, PEG        | Tube feeding    | 4                | DOD (aspiration pneumonia) |
| 12  | 56/M    | 1  | Definitive CCRT, 66Gy/33Fx       | 8 months                  | TEF, PRG        | Tube feeding    | 12               | Alive with no evidence of disease |
| 13  | 59/M    | 1  | Definitive CCRT, 66Gy/33Fx       | 5 months                  | TEF, PRG        | Tube feeding    | 11               | Alive with disease |

Abbreviation: PS performance status, RT radiotherapy, CCRT Concurrent chemoradiotherapy, BEF bronchoesophageal fistula, TEF tracheoesophageal fistula, PEG percutaneous endoscopic gastrostomy, PRG percutaneous radiological gastrostomy, DOD dead of disease

aBEF was newly developed at 1 month' follow-up after completion of RT. Later, closing of fistula was found at 2 months' follow-up and he performed operation and still alive with no evidence of disease
and T4b was performed [11]. For patients with stage III disease, the MS time and 2-year OS rate were 12 months and 27%, respectively. Two of five clinical T4b tumours with fistulae showed disappearance of the fistula after RT. However, the aggravation or development of a fistula was noted in five of 25 patients (20%). Another study reported the results of CCRT in patients with a fistula that developed before or during treatment [12]. The MS time was 8.5 months and the 1- and 2-year OS rates were 33 and 22%, respectively. Disappearance of the fistula was noted during or after CCRT in seven of 16 patients (44%). However, treatment was terminated early for five patients (31%) because of worsening of the oesophageal fistula, including two treatment-related deaths (13%).

In the current study, the MS time for patients treated with a curative aim was 15 months and the 1- and 2-year OS rates were 51.8 and 34.3%, respectively. A significantly increased survival was achieved in patients treated with a curative aim compared to that in patients treated with a palliative aim (p = 0.001). In addition, the CCRT group showed a better survival than that in the RT-only group (p = 0.009). Like previous studies, closing of an oesophageal fistula was observed in about half of patients with fistula before treatment (3/7, 42.9%). Fistula aggravation and newly developed fistula were observed in one patient and 13 patients, respectively. Interestingly, only one patient (1/13, 7.7%) later experienced fistula closure. Nine of 13 patients died from aspiration pneumonia. Oesophageal fistulae developed after treatment might be associated with a lower chance for closing and a higher risk for aspiration pneumonia compared to those for a fistula present before treatment.

We tried to identify risk factors for fistula development. In a previous study [13, 14], oesophageal stenosis, circumferential involvement, and elevated C-reactive protein level were associated with the risk of fistula. In the current study, disease with gross invasion on bronchoscopy showed a higher incidence of fistula development than that for disease with mucosal change (37.5% vs. 25.0%, respectively), although the difference was not statistically significant (p = 0.770). The RT dose was also not associated with the risk of fistula.

As shown above, severe complications, including fistula development and treatment-related death, have been a major challenge in the treatment of patients with clinical T4b disease with airway invasion. Thus, a strategy to reduce these severe complications is needed. Several studies demonstrated several benefits of induction chemotherapy (ICT) as an initial treatment for patients with clinical T4 disease [15, 16]. This treatment might effectively downstage the tumour, improve the resectability, anticipate treatment response, and lower the rate of fistula formation. In 2007, the results of a phase II trial of docetaxel, cisplatin, and 5-FU (DCF) followed by CCRT in patients with unresectable, locally advanced oesophageal squamous-cell carcinoma were released. In a case report of oesophageal cancer with airway invasion treated with ICT followed by CCRT [17], the planned total dose was 50.4 Gy with concurrent cisplatin and irinotecan. There was no evidence of disease until the last follow-up date. Later, the efficacy of ICT using DCF for clinical T4 oesophageal squamous-cell carcinoma was evaluated [18]. Fifty patients who underwent ICT using DCF were propensity-score-matched with 50 patients who underwent CCRT with 5-FU and cisplatin. The DCF group had significantly higher overall resectability compared to that in the CCRT group (78.0% vs. 48.0%, p < 0.01). The oesophageal perforation rate during induction treatments was significantly lower in the DCF group than that in the CRT group (4.0% vs. 18.0%, p = 0.02). The prognosis was significantly better in the DCF group than that in the CRT group (5-year cancer-specific survival 42.1% vs. 22.2%, p = 0.01).

Against this, we experienced fistulae aggravation in two of four patients after ICT with a regimen of 5-FU and cisplatin. These two patients were treated with palliative RT and all died from aspiration pneumonia during follow-up. One patient had a successful treatment with ICT followed by RT. The patient, who had a gross left main bronchus invasion of oesophageal cancer, was treated with four cycles of docetaxel and cisplatin followed by sequential RT with a total dose of 50 Gy in 20 fractions. During follow-up, there was no evidence of fistula development or disease progression until the last follow-up date. To determine the appropriate strategy for ICT, further studies on effective chemotherapeutic regimens are needed.

Our current study had several limitations. First, it was a retrospective study; therefore, some selection bias was possible. Second, there might have been chronological changes in radiotherapy techniques during the study period.

Conclusions

Even for clinical T4b disease with airway invasion, radiation therapy with a curative aim showed acceptable survival outcomes in patients with good performance status and no distant metastasis at initial diagnosis. However, the risk of fistula development associated with fatal events remains high. Further study on the association between ICT with an effective regimen and the risk of fistula development is warranted to decrease the risk of treatment and improve clinical outcomes.
Abbreviations
3D-CRT: Three-dimensional conformal RT; AJCC: American Joint Committee on Cancer; CCRT: Concurrent chemoradiotherapy; CT: Computed tomography; CTV: Clinical target volume; DCF: Docetaxel, cisplatin, and 5-FU; EGD: Esophagogastroduodenoscopy; FDG-PET-CT: 18F-fluorodeoxyglucose positron-emission tomography with CT; GTV: Gross tumour volume; ICT: Induction chemotherapy; IMRT: Intensity-modulated radiation therapy; MS: Median survival; NCCN: National Comprehensive Cancer Network; OS: Overall survival; PTV: Planning target volume; RT: Radiation therapy

Acknowledgements
Not applicable.

Funding
There is no funding relevant to this work to be declared.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
KCP, MJA, SHL, JMS, YMS, JIZ, YSC, HKK, and JHC revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Institutional Review Board (#2018 Ethics approval and consent to participate approved the final manuscript.

Consent for publication
Written informed consent for publication of their clinical details and/or clinical images was obtained from the patients.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
2Department of Medicine (Hemato-oncology), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
3Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
4Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Received: 28 August 2018 Accepted: 3 December 2018

Published online: 14 December 2018

References
1. Reed MF, Mathisen DJ. Tracheoesophageal fistula. Chest Surg Clin N Am. 2003;13:271–89.
2. Burt M, Diel HL, Martini N, Bains MS, Grinsberg RJ, McCormack PM, et al. Malignant esophagorespiratory fistula: management options and survival. Ann Thorac Surg. 1991;52:1222–8 discussion 8–9.
3. Burt M. Management of malignant esphagorespiratory fistula. Chest Surg Clin N Am. 1996;6:765–76.
4. Hernsivis A, Marzi K, al-Saraf M, Leichman L, Brindle J, Vatinovicus V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.
5. al-Saraf M, Marzi K, Hernsivis A, Leichman L, Brindle JS, Vatinovicus VK, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15:277–84.
6. Smith TJ, Ryan LM, Douglass HO Jr, Haller DG, Dayal Y, Kirkwood J, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the eastern cooperative oncology group. Int J Radiat Oncol Biol Phys. 1998;42:269–76.
7. Ishida K, Izuka T, Ando N, Ide H. Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: nine Japanese institutions trial. Jpn J Clin Oncol. 1996;26:310–5.
8. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.
9. Ahmed H, Hussein MA, Grant CE, Wadleigh RG. Closure of tracheoesophageal fistulas with chemoradiotherapy and radiotherapy. Am J Clin Oncol. 1998;21:177–9.
10. Muto M, Ohtsu A, Miyamoto S, Muro K, Boku N, Ishikura S, et al. Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae. Cancer. 1999;86:1406–13.
11. Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y, Shigeoka H. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys. 2002;53:134–9.
12. Koike R, Nishimura Y, Nakamatsu K, Kanamori S, Shibata T. Concurrent chemoradiotherapy for esophageal cancer with malignant fistula. Int J Radiat Oncol Biol Phys. 2008;70:4148–52.
13. Kawakami T, Tsushima T, Osako M, Ogawa H, Shinzawa S, et al. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study. BMC Cancer. 2018;18:573.
14. Tsushima T, Mizusawa J, Sudo K, Nonma Y, Kato K. Risk factors for esophageal fistula associated with chemoradiotherapy for locally advanced unresectable esophageal cancer. Medicine. 2016;95:20.
15. Yamasaki M, Yasuda T, Yano M, Hirao M, Kobayashi K, Fujitani K, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouraciul plus Adriamycin (ACF) as neoadjuvant chemotherapy for esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2017;28:1166–20.
16. Shirahata O, Yamasaki M, Makino T, Motoori M, Miyata H, Shinkai M, et al. Feasibility of neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil versus Adriamycin, cisplatin, and 5-fluorouracil for Repectable advanced esophageal Cancer. Oncology. 2017;92:101–8.
17. Ku GY, Goodman KA, Rusch WW, Ilson DH. Successful treatment of esophageal cancer with airway invasion with induction chemotherapy and concurrent chemoradiotherapy. J Thorac Oncol. 2009;4:452–4.
18. Makino T, Yamasaki M, Miyazaki Y, Wada N, Takahashi T, Kurokawa Y, et al. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Dis Esophagus. 2017;31:1–7.